Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Selling Takatsuki Plant to Taiyo for 37.6 Billion Yen
February 1, 2019
- Ono Grabs Asian Rights to Repare’s Pol-theta Inhibitor
February 1, 2019
- JT Files Topical JAK Inhibitor in Japan for Atopic Dermatitis
February 1, 2019
- FDA Nixes Sunovion’s Parkinson’s Drug, but Requires No New Studies
February 1, 2019
- Fycompa Filed for Monotherapy, Pediatric Use in Japan: Eisai
January 31, 2019
- Merck Serono Files Bavencio in Japan for First-Line Use in RCC
January 31, 2019
- Takeda’s Tetravalent Dengue Vaccine Succeeds in PIII Study
January 31, 2019
- Chugai to Transfer Japan Rights for 3 Topical Maxacalcitol Products to Maruho
January 31, 2019
- Kymriah Study Drugs to Be Manufactured in Kobe: Novartis
January 30, 2019
- Stem Cell Therapy SB623 Misses Key Target in US PIIb Study for Stroke: SanBio, Sumitomo Dainippon
January 30, 2019
- Protosera, Fujita Health Univ. Tie Up for Research to Develop Treatments for Autism Spectrum Disorder
January 30, 2019
- China Approves Latuda for Schizophrenia: Sumitomo Dainippon
January 30, 2019
- Takeda to Book 38 Billion Yen Gain from Sale of Osaka HQ, Other Assets
January 29, 2019
- Ex-MHLW Bureau Chief Takeda Tapped as Senior Adviser at BCG
January 29, 2019
- Nippon Express to Set Up 4 Distribution Centers for Full-Scale Drug Logistics Biz, Aims for 15 Billion Yen Annual Sales
January 29, 2019
- Xofluza Enjoys Commanding Lead with 47% Share in October-December, MHLW Data Show
January 28, 2019
- Tamiflu Generics, Too, in Tight Supply amid Spike in Flu Patients
January 28, 2019
- Sun Pharma Poised to Raise Profile in Japan Dermatology Space, Generics and New Drugs Alike
January 25, 2019
- Takeda’s Specialty Business Unit Boots Up with Entyvio Detailing
January 25, 2019
- Shionogi, PeptiDream Join Forces for Novel Peptide Drug-Conjugate Discovery Research
January 24, 2019
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…